
|Videos|July 26, 2022
Fezolinetant making waves for VMS
Author(s)Morgan Ebert, Managing Editor
Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections
2
FDA clears FemVue Controlled for in-office tubal assessment
3
Michelle Manzo, MPH, CMPP, discusses epilepsy challenges in motherhood
4
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more
5









